UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 177 filers reported holding UNIQURE NV in Q4 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $100,979 | +43.7% | 15,055 | +145.5% | 0.00% | – |
| Q2 2023 | $70,247 | -46.4% | 6,133 | -5.8% | 0.00% | – |
| Q1 2023 | $131,124 | -8.9% | 6,513 | +3.1% | 0.00% | – |
| Q4 2022 | $144,000 | -5.9% | 6,320 | -22.0% | 0.00% | – |
| Q3 2022 | $153,000 | -10.0% | 8,099 | -10.6% | 0.00% | – |
| Q2 2022 | $170,000 | +6.9% | 9,060 | +3.2% | 0.00% | – |
| Q1 2022 | $159,000 | -8.6% | 8,778 | +5.8% | 0.00% | – |
| Q4 2021 | $174,000 | -51.4% | 8,299 | -25.7% | 0.00% | -100.0% |
| Q3 2021 | $358,000 | +2.3% | 11,163 | -1.6% | 0.00% | 0.0% |
| Q2 2021 | $350,000 | -29.3% | 11,350 | -22.7% | 0.00% | 0.0% |
| Q1 2021 | $495,000 | +19.0% | 14,689 | +27.4% | 0.00% | 0.0% |
| Q4 2020 | $416,000 | +2.2% | 11,529 | +4.1% | 0.00% | 0.0% |
| Q3 2020 | $407,000 | +23.7% | 11,071 | +51.9% | 0.00% | 0.0% |
| Q2 2020 | $329,000 | -3.8% | 7,286 | +1.2% | 0.00% | 0.0% |
| Q1 2020 | $342,000 | – | 7,202 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 155,500 | $11,803,000 | 2.66% |
| Aquilo Capital Management, LLC | 901,490 | $16,290,000 | 2.39% |
| Nantahala Capital Management | 2,811,459 | $50,803,000 | 2.25% |
| Privium Fund Management B.V. | 493,229 | $8,913,000 | 1.97% |
| 683 Capital Management, LLC | 1,355,000 | $24,485,000 | 1.31% |
| Henry James International Management Inc. | 125,622 | $2,270,000 | 0.90% |
| Integral Health Asset Management, LLC | 170,000 | $3,072,000 | 0.80% |
| Nantahala Capital Management | 890,000 | $16,082,000 | 0.71% |
| Sonic Fund II, L.P. | 50,000 | $904,000 | 0.51% |
| Voss Capital, LLC | 70,000 | $1,265,000 | 0.40% |